Podcasts about dupixent

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's new long-acting amylin injection, met-233i, has shown promising weight loss results over eight months, leading to a rise in shares. Meanwhile, CDC vaccine advisors are either being pushed out or leaving their positions. Other top stories include Sirna's expansion beyond the liver, Keros returning $375 million to investors, and ACIP members receiving termination notices. In vitro cell research is focused on slowing aging and preventing age-related diseases. Updates on Merck's oral PCSK9 inhibitor, Sanofi and Regeneron's Dupixent effectiveness, and Avidity's muscular dystrophy drug are also highlighted.The expansion of RNA therapeutics is discussed, with multiple companies aiming to target small interfering RNA to various organs by 2030. Uniqure's regulatory progress in developing a gene therapy for Huntington's disease has sparked optimism, although past disappointments for patients are noted. Perspective Therapeutics presents new data on neuroendocrine tumor treatment at ASCO25. Concerns about RFK Jr.'s vaccine campaign and its potential to increase distrust in vaccines are raised in the editorial. Cancer news, cell and gene therapy updates, upcoming events, job listings, and a call for reader suggestions on coverage topics are also covered.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 6 June 2025. In this episode: Sanofi's Blueprint buy; AstraZeneca's breast cancer resistance results at ASCO; BMS and BioNTech's big bispecific deal; Kymera's Dupixent in a pill; and Degron's CEO on pipeline and strategy. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-T5ID4HF465BXFGAH7C6OOSEGTA/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Download the transcript here

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Listen to the podcast here

Eine Spritze gegen Neurodermitis? Viele von euch stehen irgendwann vor der schwierigen Entscheidung, ob eine innerliche Behandlung für euer Kind infrage kommt und haben dabei (völlig nachvollziehbar!) jede Menge Fragen und Bedenken. In dieser Folge erzählt Thimea, Mama einer kleinen Tochter mit schwerer Neurodermitis, wie das Medikament Dupixent ihren Familienalltag grundlegend verändert hat – und warum sie trotz Nebenwirkungen jederzeit wieder „Ja“ dazu sagen würde.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. In a recent interview with former Fox News journalist Megyn Kelly, FDA Commissioner Marty Makary discussed a potential new mechanism-driven pathway for expedited rare disease approvals, as well as the possibility of certain environmental factors contributing to autism. Despite Makary's announcement of a directive to limit industry participation in the FDA's advisory committees, industry involvement is actually required by a 1997 law, and banning industry representatives would not have a significant impact. Additionally, the FDA recently approved Sanofi/Regeneron's Dupixent for chronic hives after initially rejecting it, and Lilly has promised to manufacture a weight-loss pill in the US following a Phase III win. The newsletter also includes other news stories, opinions, and upcoming events in the biopharmaceutical industry.

We saw more action on the M&A front this week as Novartisbought back its blood thinner abelacimab and the rest of Anthos Therapeutics for up to $3.1 billion and still ahead, a potential buyout of SpringWorks Therapeutics by Merck KGaA, which confirmed it's in “advanced discussions” with the biotech. Meanwhile, Eli Lilly signed aglobal licensing deal for a MASH asset with South Korea's OliX Pharmaceuticals.As Q4 and full-year 2024 earnings continue to roll in, BMS, Eli Lilly,Novo Nordisk, AstraZeneca, Eisai, Vertex and Gilead all reported their results in the past week. Notably, BMS continues to reorganize, now targeting an additional $2 billion in savings through 2027, and AstraZeneca axed two rare disease drugs from its $39 billion acquisition of Alexion. When it comes to revenue growth, Novo's Wegovy and Lilly's Zepbound continue to climb at a striking pace—a phenomenon that has at times driven the weight loss drugs into shortage and spawning a controversialshadow market of off-brand versions.Speaking of controversy, Regeneron is suing its Dupixent partner Sanofi, claiming the French pharma has failed to provide it with adequate information regarding sales of the blockbuster anti-inflammatory drug—which missed analyst expectations in Q4.On the clinical side, the pulmonary fibrosis space continues to see positive results, with Boehringer Ingelheim notching its second Phase III win in six months for nerandomilast. It wasn't all good news, however, as Pliant Therapeutics suspended dosing and enrollment in a Phase IIb/III study of its idiopathic pulmonary fibrosis candidate, causing its stock to crash.Finally, BioSpace released a special edition of ClinicaSpace this week focused on the resurgent cardiovascular space—just in time for Valentine's Day! Sign uphere to receive your copy.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Bristol Myers Squibb is seeking to broaden the use of its CAR T cell therapy, Breyanzi, to address marginal zone lymphoma as a strategy to offset losses from exclusivity. In other news, Boehringer Ingelheim has seen promising results in a Phase III trial for its lung fibrosis drug, randomilast, aimed at progressive pulmonary fibrosis. However, Pliant has experienced a stock decline following the halt of its Phase IIb/III study for idiopathic pulmonary fibrosis. Additionally, Vertex has received FDA approval for its non-opioid pain treatment, while AbbVie has secured approval for a new antibiotic. Bain's acquisition of Tanabe for $3.3 billion is also making headlines. Regeneron is currently in a legal battle with Sanofi over the Dupixent pact, and Equillium's itolizumab is undergoing testing against Humira for ulcerative colitis. On the horizon, Acelyrin and Alumis are joining forces to address immune-mediated diseases, while Eisai is seeking subq approval for Leqembi due to sluggish US sales. Job opportunities are available at ATCC, AbbVie, Regeneron Pharmaceuticals, and Dren Bio.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eisai reports lagging sales of Leqembi in the US and is now looking towards gaining approval for a subcutaneous version. Novo Nordisk executives are trying to boost sentiment after the failure of obesity candidate Cagrisema, without providing hard numbers. Regeneron is suing Sanofi for allegedly withholding information about the sales of Dupixent. Nasdaq newcomers Acelyrin and Alumis have merged to focus on immune-mediated diseases. The AAPS National Biotechnology Conference will cover trends in research and biopharma markets.Equillium's Itolizumab is competing with Humira in ulcerative colitis. FDA approval of Vertex's non-opioid Jornavx signals a new era in pain treatment. Novo's bispecific for hemophilia has aced a phase III pediatric trial. Lilly has increased Zepbound supply, prompting analysts to question if it is sustainable. BMS has added $2 billion to cost-cutting plans and is eyeing deals after the success of Cobenfy. AstraZeneca has axed two Alexion assets as Q4 earnings exceed expectations.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.Roche is planning to be cautious with high-priced deals in 2025, prioritizing putting science at the center of its business development decisions. Sanofi's recent earnings were driven by Dupixent and a new RSV vaccine, with a strong focus on R&D and potential M&A deals. Inhibikase has decided to scrap a Parkinson's drug after disappointing mid-stage data, adding to recent setbacks in the field. RFK Jr. faced a divided Senate during his confirmation hearing for HHS secretary, downplaying concerns about his previous anti-vax statements. Vertex is awaiting the FDA verdict on a non-opioid pain drug, while Ironwood has made the decision to cut half of its staff due to disappointing 2025 guidance. Zentalis is planning to lay off 40% of its staff in order to extend its cash runway. The life sciences scene in the Chicago area continues to show growth.In the latest news, The Weekly covers RFK Jr.'s Senate hearing, Sage's rejection of Biogen, and developments in the obesity space. Thank you for tuning in to Pharma and Biotech Daily.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA has paused Novavax's investigational flu and COVID-flu vaccines due to a serious adverse event of motor neuropathy. This affects their COVID-flu combo and standalone flu vaccines, which were about to enter phase III testing. Meanwhile, Takeda has decided to terminate its partnership with Wave on a Huntington's disease program after investing $260 million. Novavax shares have slid due to the FDA pause, while GSK is suing Moderna for patent infringement on COVID-19 and RSV vaccines. Sanofi is also preparing to sell its consumer healthcare business.Artificial intelligence (AI) is playing a significant role in accelerating innovation in biopharma, particularly in drug development. While AI is infiltrating various stages of the process, it is not replacing human input entirely. One example of AI's impact is seen in Regeneron and Sanofi's Dupixent, which is expected to dominate the COPD biologics market with predicted revenues exceeding $6.5 billion within a decade. Additionally, Sanofi's move to sell its consumer healthcare business follows a trend among big pharma companies offloading such divisions.In the realm of biologics discovery, harnessing the power of AI and patent data can revolutionize the industry. Despite challenges related to limited access to high-quality, fair-compliant data, leveraging patent information can fill this gap and drive innovation in drug development. Takeda has walked away from its partnership with Wave Huntington after investing $260 million in the collaboration. J&J has announced Q3 earnings, including scrapping pipeline assets and raising full-year guidance. Novo's $16.5 billion buyout of Catalent faces scrutiny amid an FTC review, while GSK has sued Moderna for alleged patent infringement.Overall, the biopharma industry continues to evolve with the integration of AI, strategic partnerships, regulatory changes, and financial developments shaping its landscape.

Eczema is also known as a form of Atopic Dermatitis (AD). Males and females are not equally affected by AD, and studies have shown that AD is more common among males during infancy and childhood. However, around puberty, there is a shift towards more females than males having AD and this female predominance continues into adulthood. Eczema can impact any women during pregnancy. In fact, it is the most common prenatal skin condition. A majority of women with eczema in pregnancy have never it previously diagnosed. Actually, approximately 60%–80% of prenatal eczema patients have no prior history of the condition. Eczema in pregnancy may occur because of changes in hormones and the immune system. During pregnancy, the body's immunity shifts a bit and this shift in immunity can make the mother more sensitive to allergens and dermal manifestations vis inflammatory mediators. Those with preexisting common hay fever or other allergies before pregnancy may be at higher risk of developing eczema during pregnancy. Eczema isn't just about “itchy skin”, for some it has severe skin manifestations and affects quality of life. While biologics are generally not initiated in pregnancy except for very severe cases, some women may be on this medication when ENTERING pregnancy. Are they safe to use? We have new SURPRISING data from September 2024 which will help us in our shared-decision making with our patients. Listen in for details.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Bristol Myers has received approval for a first-of-its-kind schizophrenia drug, Cobenfy, and plans to sell it despite potential insurance barriers for patients. Biogen and UCB are planning a large study for their lupus medicine, Biohaven is seeking approval for a neurological disorder drug, and Amgen claims success for immune drugs. Scientist.com discusses streamlining IND applications for cell and gene therapy innovations, while Arch raises $3 billion for a biotech fund. The article also covers strategies to keep clinical trials on schedule and provides insights into the market strategies of drugmakers. Additionally, upcoming events and trending news in the biopharma industry are highlighted. Biopharma Dive offers in-depth journalism and insights into the biotech and pharma industries, covering topics such as clinical readouts, FDA approvals, gene therapy, drug pricing, and research partnerships.Bristol Myers Squibb (BMS) has received FDA approval for KarXT, the first new schizophrenia therapy in 35 years. The drug targets muscarinic receptors and is considered ahead of competition from AbbVie and Neurocrine Biosciences. Pfizer's withdrawal of Oxbryta has left the sickle cell community scrambling, as the therapy was predicted to reach $750 million in sales. Sanofi and Regeneron's Dupixent has received approval for use in chronic obstructive pulmonary disease. The FDA's oncology drugs advisory committee has recommended limiting the use of Keytruda and Opdivo in stomach and esophageal cancer patients with low PD-L1 expression. Additionally, AbbVie's acquisition of Cerevel is showing promise with a phase III win in Parkinson's disease. Cassava has agreed to pay a $40 million fine to resolve an SEC probe, while Roche is looking to push Gazyva into lupus nephritis with positive late-stage data. Lilly is facing scrutiny over drug pricing compared to Novo Nordisk. The BACE credential is highlighted as a way to advance a career in the biotech industry.Senators have introduced a bill to establish cybersecurity standards for healthcare providers, health plans, and business associates. A study found that hospital acquisitions provide a one-time efficiency boost to margins but do not continue to improve operating metrics in the long term. Canopy CEO Shan Sinha discusses healthcare workplace violence and technology's role in protecting workers. The unexpected consequences of hospital quality scores are explored, suggesting a reexamination of the federal hospital-acquired condition reduction program. AI is being integrated into healthcare to give back time and prioritize people in day-to-day tasks. In other news, hospitals in Florida are preparing for Hurricane Helene, a major U.S. prison is criticized for substandard healthcare, and families in states banning health care for transgender teens may have to travel for care. Healthcare Dive provides in-depth journalism on topics such as health IT, policy, insurance, and more for decision-makers in the industry.The FDA recently approved Bristol Myers Squibb and Karuna Therapeutics' new drug, KarXT, now known as Cobenfy, for schizophrenia. This marks the first new mode of action approved for the condition in decades. The drug showed promising results in clinical trials, with patients on Cobenfy actually losing weight compared to gaining weight on other medications. However, there is still room for improvement as over 50% of patients discontinued treatment. The approval of Cobenfy highlights Bristol Myers Squibb's deal-making skills and sets the stage for a new generation of treatments for schizophrenia. Other upcoming drugs in the field may further shake up the market. Pharmaceutical companies are continuously working on market strategies to successfully launch new drugs post-FDA approval, as turning a new drug into a successful asset remains a challenge in the

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. This week's commercialization news includes Dupixent's success in a chronic hives study, Lilly's development of a weekly insulin shot, and BioMarin's plans for growth. The House backs a bill restricting China's role in US biotech, while Lykos CEO is set to depart after FDA rejection and layoffs. The newsletter also discusses key developments in cell therapy and offers insights on utilizing a direct-to-patient model in the healthcare industry. Various resources and upcoming events in the biopharma industry are also highlighted. Biopharma Dive provides in-depth journalism and insights into the latest news and trends shaping the biotech and pharma industries.BridgeBio has reduced its gene therapy budget after data from a trial on an adrenal gland medicine did not meet the company's investment threshold. GlaxoSmithKline has discontinued a herpes vaccine after it did not meet efficacy goals in a phase 2 study. Roivant has launched a new 'vant' focused on a hypertension drug. Centessa's sleepiness drug has shown promising results in early studies, leading to a rise in the company's shares. Additionally, Dupixent has succeeded in a chronic hives study, giving Sanofi and Regeneron a chance to resubmit their application for approval. Investors are also paying attention to Centessa's sleepiness drug. This news comes alongside updates on other pharmaceutical developments, such as Saxenda's effectiveness for children as young as 6 and Roche's expansion of R&D labs. Additionally, the newsletter covers upcoming events and resources for biopharma professionals. Biopharma Dive provides in-depth coverage of news and trends in the biotech and pharma industries, including clinical trials, FDA approvals, gene therapy, drug pricing, and research partnerships.Iowa has awarded Centene's subsidiary, Iowa Total Care, a Medicaid managed care contract worth $2.8 billion. Telehealth groups are urging Congress and the White House to extend controlled substance virtual prescribing before pandemic-era flexibilities expire. The Biden administration has finalized a rule raising mental health coverage standards for private plans. Steward Health Care received court approval to sell its three most valuable hospitals to Orlando Health for $439 million. The importance of data quality in realizing value from medical imaging data is emphasized by Enlitic. Payers are encouraged to optimize quality and grow revenue through key strategies in an upcoming webinar. Healthcare Dive provides in-depth journalism and insight into the most impactful news and trends shaping healthcare across various sectors like health IT, policy & regulation, insurance, digital health, payer-provider partnerships, and value-based care.Novo Nordisk showcased its investigational GLP-1 pill that resulted in a remarkable 13% weight loss. This comes after positive Phase I results for the pill, which analysts compared to weight loss pills being developed by Lilly and Pfizer. Expanded coverage for cardiovascular disease under Medicare could have significant implications for Novo's obesity drug, Wegovy. Analysts estimate that the expansion of Wegovy's label beyond obesity could lead to an annual Medicare spending of $145 billion. Meanwhile, GSK has abandoned the development of its herpes vaccine after disappointing Phase I/II results, and Crispr Therapeutics and Vertex Pharmaceuticals are facing challenges in making their sickle cell gene therapy profitable. Novo's other drug, Saxenda, was found to effectively and safely lower BMI in children, according to a study published in NEJM. Additionally, Lilly continues to make progress with its once-weekly insulin, while Bain has raised $3 billion for a fund supporting life sciences companies. The biopharmaceutical industry continues to see changes, with Biomarin facing challenges and Terns moving forward in the obesity spac

There's never been a better time to be a CSU patient, with cutting-edge therapies and revolutionary treatments just around the corner. As research accelerates, new and promising options that could significantly improve the quality of life for those living with Chronic Spontaneous Urticaria are coming to market. In this episode, Dr. Matthew Zirwas joins us to discuss the latest advancements in treating CSU, offering invaluable insights into both current and emerging treatment options. With his extensive experience and patient-centred approach, Dr. Zirwas breaks down the complexities of CSU and highlights how these new therapies can make a real difference. This podcast was made in partnership with Allergy & Asthma Network. We thank Novartis for sponsoring this podcast. What We Cover in Our Episode About Emerging Chronic Spontaneous Urticaria Treatments: How Dr. Zirwas explains CSU to his patients: Discover the patient-friendly explanations that help demystify CSU and empower patients to learn more about their disease. When to start with a biologic: Learn about the decision-making process for initiating biologic therapies like Xolair (omalizumab) and when they are most appropriate. The new medications coming to market: Get an overview of the latest advancements, including: Dupixent (dupilumab): A biologic administered via injection that targets key pathways in the inflammatory response. Remibrutinib: A BTK (Bruton tyrosine kinase) inhibitor available as a pill that blocks a crucial enzyme in mast cell activation. Barzolvolimab: A promising biologic that targets the C KIT receptor on mast cells to reduce their number. Shared decision-making with these medications: Explore strategies for choosing the most appropriate treatment in a rapidly evolving therapeutic landscape. Research into the underlying cause of CSU: What's happening on the research front to uncover the root causes of CSU. About Our Guest Dr. Matthew Zirwas, MD, is a board-certified dermatologist and a nationally recognized expert in allergy patch testing, psoriasis, and eczema. He founded the Bexley Dermatology Research Clinic, offering patients access to the latest treatment options before they are widely available. Dr. Zirwas also serves as a dermatologic advisor for several companies, including ALL Laundry Detergent and Cerave, and contributes to Women's Health Magazine. Learn more about Dr. Zirwas. More resources about chronic spontaneous urticaria:  Chronic Urticaria Management, Resources & Glossary of Terms: https://allergyasthmanetwork.org/health-a-z/chronic-urticaria/management-and-resources/ What is Chronic Urticaria: https://allergyasthmanetwork.org/health-a-z/chronic-urticaria/  More information about Omalizumab (Xolair): https://www.xolair.com/chronic-spontaneous-urticaria.html Disclaimer: This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Steward, a bankrupt healthcare organization, is set to sell its physician group to a private equity firm for $245 million. Kaiser's operating margin has risen to 3.1% in the second quarter, indicating a strong performance for the nonprofit giant. Stryker is acquiring smart hospital technology firm care.ai to enhance its health IT offering. For-profit health systems have seen an increase in Medicaid supplemental payments in the second quarter, although executives state it is not enough to cover costs. The importance of integrating generative AI in the healthcare landscape is highlighted, with tips on selecting the right vendor for AI solutions. The newsletter also includes insights on using data to improve patient outcomes and transforming healthcare through tailored change management strategies.Transitioning to the next news segment:Lilly has opened a new R&D hub in Boston, while Ovid and Lexicon have laid off staff. Biotech M&A activity is increasing, with Crown Laboratories acquiring Revance Therapeutics. Galderma has received FDA approval for Nemluvio, a competitor to Dupixent for treating prurigo nodularis. Biotech IPOs are crucial for the industry, with Actuate Therapeutics recently pricing its IPO. A journal retracted papers on MDMA-assisted therapy following FDA rejection. Companies like Pfizer and Lilly are focusing on patient-centric commercialization strategies. Key events include a webinar on increasing a drug's chances of reaching the commercial market and company announcements from Procdna, Authenticx, and others.Moving on to the next segment:Atai, a biopharmaceutical company, has seen early success with its psychedelic depression drug in a phase Ib study. This comes after the FDA rejected another company's MDMA-assisted PTSD therapy. Galderma's IL-31 injection has received FDA approval for the skin disorder prurigo nodularis, with potential for use in atopic dermatitis. Novo Nordisk is continuing to pursue its insulin icodec program, aiming to file a combination with semaglutide by the end of the year. Q2 earnings for biopharma companies have been mixed, with some exceeding expectations while others faced challenges due to the COVID-19 pandemic and vaccine issues. The role of Quality Assurance and Regulatory Affairs (QARA) professionals is becoming increasingly important in the biopharma industry, transitioning from the factory floor to the boardroom.Transitioning smoothly to the next news:Gain Therapeutics is making strides in developing a potential treatment for Parkinson's disease that targets alpha synuclein through a small molecule that binds to an enzyme coded by a specific gene. This approach aims to modulate the underlying biology of the disease. The company's chief medical officer, Dr. Jonas Hannestad, emphasized the importance of biomarkers in neurodegenerative drug development to monitor the effectiveness of treatments. Gain Therapeutics faces challenges in financing, but their innovative approach could change how Parkinson's disease is treated.Additionally, an emerging drug candidate for multiple sclerosis from Immunic has shown promising safety and antiviral effects.Transitioning smoothly again:Liquid I.V. is running a multichannel campaign called "Indulge in Hydration" to help consumers beat the summer heat. The campaign includes augmented reality activations, Netflix ad testing, and a Spotify takeover. Oreo and Coca-Cola have partnered to create a drink and cookie combination featuring the iconic brands, with a marketing campaign centered around "besties." LG is boosting its home appliances with a competition show on Prime Video called "Estate of Survival." WPP has downgraded its full-year outlook as it works to modernize its offering.Concluding this episode:This week in biotech Support the Show.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The biotech industry is experiencing significant growth, with drugmakers in the U.S. and Europe raising $6.8 billion in venture capital funding in the first three months of the year. This trendline explores the evolving biotech market and highlights hotspots of startup activity. Stories included focus on an unorthodox investment firm supporting biotech's 'infrastructure', the rise in private biotech funding, and insights from biotech landlord Alexandria on research clusters and the sector's recovery.A study presented at the Alzheimer's Association International Conference showed that Novo Nordisk's GLP-1 drug liraglutide may slow cognitive decline in Alzheimer's patients by 18% compared to placebo over one year of treatment. Additionally, Novo's diabetes drug Ozempic was found to be linked to a lower risk for tobacco use disorder. Pfizer and Merck reported strong second-quarter earnings exceeding Wall Street expectations. Novo Nordisk's Ozempic was also found to potentially help diabetics quit smoking according to new research. Other news includes AstraZeneca's Calquence achieving positive results in a Phase III trial for CLL and Ventyx ending development of a Tyk2 inhibitor after a Phase II flop in Crohn's disease.Pfizer has decided to quit its Duchenne gene therapy program, resulting in the termination of 150 staff members. Incyte has also trimmed its cancer drug pipeline by discontinuing the development of five experimental treatments. The biotech market is seeing an increase in M&A activity, with companies like Boehringer making deals to add to their cancer drug pipeline. Overall, the industry is evolving with a focus on efficiency, effectiveness, and ethical innovation in clinical research.Sanofi's recent record sales quarter for its immunology drug Dupixent has boosted the company's confidence in its long-term strategy, following a previous dip in share value due to growth target adjustments. The company's spinoff of its consumer unit Opella is part of a trend among big pharma companies to focus on biopharma futures. Sanofi's Dupixent, with an expanding list of indications, is showing long-term value for the company and has the potential to become one of the best-selling drugs in the world by the end of the decade.Cleveland Clinic has appointed its first Chief AI Officer, Ben Shahshahani, to lead the health system's AI strategy, focusing on managing safety, ethics, and data security concerns. Healthcare organizations are facing obstacles in increasing patient response rates through phone communication. Healthcare Dive provides insights and news for healthcare leaders, covering various topics such as health IT, policy & regulation, insurance, digital health, payer-provider partnerships, and value-based care.GSK has partnered with Flagship to help find new drugs and vaccines, similar to recent alliances with Pfizer and Novo Nordisk. Boehringer has acquired startup Nerio for up to $1.3 billion to expand its cancer drug pipeline. Autobahn raised $100 million for neuropsych drugs, while a startup led by former J&J executives, Third Arc Bio, raised $165 million for cancer and immune disease drugs. The competitive market for obesity drugs is growing, with analysts expecting significant revenue from drugs like Novo's and Eli Lilly's.Biopharma Dive provides in-depth coverage of industry news and trends, covering topics from clinical trials to drug pricing and research partnerships.Support the Show.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Edwards recently made two acquisitions totaling $1.2 billion in the heart device sector, while also reporting a slowdown in its core business. Owens & Minor agreed to a $1.36 billion takeover of Rotech to expand its home medical equipment offerings. Inspire Medical's COO is leaving to become CEO of a cardiology-focused medical device company. CDRH director Shuren is stepping down after 15 years, with Michelle Tarver serving as acting director. Boston Scientific anticipates strong growth for Farapulse after a successful launch, reflecting the ongoing trends and changes in the medtech industry.Tenet's earnings beat expectations, prompting an increase in full-year guidance. Hill Democrats are working to codify the Chevron doctrine, with a bill introduced by Warren and other lawmakers. Adventist Healthcare has appointed a new CEO, while PBMs are facing scrutiny from lawmakers. Molina's Medicaid growth offset redetermination pressures in Q2. AI is being used to transform unstructured patient data into structured reports, as well as in clinical trial protocol development. Overall, the healthcare industry is experiencing shifts and reforms as various players navigate challenges and opportunities.Sanofi's immunology pipeline shows promise as sales of Dupixent rise, Viking plans to accelerate its obesity drug into late-stage testing, and Kamala Harris takes a stance on key pharma issues. Warren and Democratic lawmakers introduce a bill to revive the Chevron doctrine, while Pfizer's hemophilia gene therapy meets late-stage study goals. The pharma industry is racing to develop GLP-1 drugs for obesity treatment, with the market expected to surpass $100 billion. The newsletter covers a range of topics in biotech and pharma, including clinical trials, drug pricing, gene therapy, and more. Biopharma Dive provides in-depth journalism and insight into the most impactful news and trends in the industry.AI-designed drugs have shown promising results in phase 1 testing, with an 80%-90% success rate compared to traditionally developed drugs. However, in phase 2, the success rate falls closer to the industry average of 40%. The sample size of phase 2 candidates was small, with just 10 drugs included, as few AI molecules have advanced that far. Despite this, pharma companies and biotech investors are still backing the AI dream, with companies like Mubadala Capital investing in life sciences companies leveraging AI platforms for drug R&D. The future success of AI-designed drugs in clinical trials remains to be seen as more AI molecules progress through the pipeline. Meagan Parrish discusses where Alabdallah of Mubadala Capital sees promise in biotech and why he continues to support AI platform companies for drug development. Additionally, the newsletter covers Kamala Harris' stance on key pharma issues, tips for a successful therapeutic launch, and resources on testing cognition in Alzheimer's disease clinical trials and using data to upgrade drug commercialization strategies.

Is joining a club the key to healing our fractured nation? Would a robot be better than Katie Nolan at bartending? Would you cover your face in fish sperm for dermatological reasons? PLUS: the worst drink to order from a bartender, Dr. Dupixent, frankincense, myrrh, and late-breaking country music news. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Is joining a club the key to healing our fractured nation? Would a robot be better than Katie Nolan at bartending? Would you cover your face in fish sperm for dermatological reasons? PLUS: the worst drink to order from a bartender, Dr. Dupixent, frankincense, myrrh, and late-breaking country music news. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Meta-analysis shows NO excessive bleeding problems with Omega-3s; Fish oil found safe for surgery; Dupixent for nasal polyps? Remedies for SIBO (small intestine bacterial overgrowth) in a type 1 diabetic; Less than 5% of the world's population reside in the U.S.—but we consume 65% of the medications! Dr. Oz heart device under scrutiny; Oregon court reverses liability shield for Bayer in Round-Up class action; Movie Review—“Pain Hustlers”, a fictionalized recreation of a real-life opioid medication scandal.

Pediatric eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that affects millions of children worldwide. Dr. Hannah Kopelman and Dr. Lawrence F. Eichenfield discuss the latest advancements in managing pediatric eczema. They explore new treatment options like SOTYKTU, Adbry, and JAK inhibitors/biologics, focusing on symptom management and comprehensive care. The discussion highlights the promise of drugs such as Dupixent and lebrikizumab, the importance of individualized treatment plans, and the need for ongoing research to better understand the causes of eczema and develop prevention strategies and potential cures. Guest Bio: Dr. Lawrence F. Eichenfield is a distinguished pediatric dermatologist at Rady Children's Hospital in San Diego, specializing in eczema and autoimmune skin disorders. With extensive experience in clinical practice and research, he has significantly advanced pediatric dermatology. Connect with me across Social: Instagram:https://www.instagram.com/drhannahkopelman/ TikTok: https://www.tiktok.com/@drhankopelman Twitter: https://twitter.com/drhankopelman Pinterest: https://www.pinterest.com/drhankopelman/ Blog: https://www.hannahkopelman.com/blog/ The content of this podcast is for entertainment and educational purposes only. This content is not meant to be a substitute for medical advice or treatment for any medical condition. --- Send in a voice message: https://podcasters.spotify.com/pod/show/hannah-kopelman/message

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:  The good — J&J depression drug aces late-stage trial The bad — Takeda plans layoffs at Massachusetts sites The ugly —  FDA delays review of Sanofi-Regeneron's Dupixent in COPD

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.## The healthcare industry is facing various challenges, including nursing homes suing to block a staffing mandate, healthcare organizations not being prepared for cyberattacks, the impact of Ascension's cyberattack, and a house committee targeting healthcare consolidation. Trends in addressing social determinants of health and site-neutral payments are also discussed. A report shows that over a third of healthcare organizations lack a cyberattack contingency plan. Stay informed on healthcare news and trends through the Healthcare Dive newsletter.## Data-driven marketing strategies are crucial for success in today's competitive landscape. Marketers are using data to optimize campaigns and gain insights into consumer behavior. Examples include Pop-Tarts Bites using data to improve ad recall and engagement rates. Legacy media investing in connected TV, retail media convergence, the impact of cookie deprecation on marketing strategies, and the latest trends in marketing data are also covered. Marketing Dive delivers this content to subscribers as part of their newsletter subscription.## AstraZeneca aims to expand its cancer drug sales, while Pfizer and Lilly enter the direct-to-consumer market online. The European Commission declines to revoke approval of PTC Duchenne drug, calling for a new review. Amgen's drug for tough-to-treat lung cancer receives FDA approval, and Regeneron faces new biosimilar threats. An AI biotech has laid off staff, with companies focusing on immune disease research and treatments. Moderna wins a patent dispute, Walgreens and CVS rethink their pharmacy business, and weight-loss drug shortages affect patients. Biopharma Dive provides news and insights on biotech and pharma trends.## AstraZeneca plans to achieve $80 billion in annual revenue by 2030, launching 20 new drugs before the end of the decade. Bio lays off 30 employees as Congress moves forward with the Biosecure Act. Lilly signs a potential $1.1 billion deal with Aktis Oncology for radiopharmaceuticals, GSK's long-acting asthma drug shows positive results in Phase III trials, FDA approves interchangeable biosimilars to Regeneron's Eylea, strong Phase III data for Dupixent by Sanofi and Regeneron, and AltruBio raises $225 million in Series B funding.## AstraZeneca invests $1.5 billion in an antibody-drug conjugate (ADC) manufacturing plant in Singapore. The global market for GLP-1 receptor agonists is projected to reach $125 billion by 2033. Gilead highlights positive results for a liver disease drug, while Rapport Therapeutics and Telix Pharma file for IPOs. Sino Biological offers recombinant cytokines for cell culture research. Bayer announces 1,500 layoffs as part of a company overhaul.## Humana CEO Bruce Broussard steps down on July 1, with current COO Jim Rechtin taking over. Inpatient admissions boost revenue for for-profit providers in Q1. The US increases tariffs on medical products from China to boost domestic production. Black Basta ransomware targets critical infrastructure providers, causing concern among authorities.## Bayer undergoes layoffs as part of a company shake-up led by CEO Bill Anderson. FogPharma and ArtBio collaborate on designing a new radiopharma drug. Sands Capital raises a $555 million fund for biotech 'crossover' investing.## Big pharma companies pledge $2.16 billion in investments in France to boost global manufacturing and research capabilities. Interest grows in cancer vaccines as a potential breakthrough in immunotherapy.## Ascension confirms a ransomware attack leaving its computer systems offline. Insurers see elevated utilization in Q1 with minimal financial impact from cyberattacks.## The biotech industry sees a surge in cell and gene therapy technologies with biosimilar uptake showing mixed results. Novartis' biosimilar sales grow while Boehringer Ingelheim's biosi

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Galderma prepares to take on Dupixent; Pfizer's plans for Adcetris in DLBCL; Lilly's donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS's CDTO Greg Meyers. https://scrip.citeline.com/SC149962/Quick-Listen-Scrips-Five-MustKnow-Things

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The biopharma industry is facing challenges with the rocky launch of Roctavian by Biomarin, as well as the departure of AbbVie CEO Richard Gonzalez. Frontier is making strides in developing a better KRAS drug with support from Galapagos. J&J has received EMA backing for earlier CAR-T use in multiple myeloma, and a NEJM paper explores a remarkable CAR-T result in autoimmune disease. Biosimilars are gaining traction in 2024 despite initial hurdles, reflecting an increase in market presence.Sanofi and Regeneron's Dupixent are undergoing a speedy FDA review for potential use in COPD, with a decision expected by June 27, 2024. AbbVie's success with Humira serves as a model for navigating the patent cliff, under the leadership of Richard Gonzalez. Frontier Medicines secures $80 million in Series C financing, while Blueprint's cancer drug Gavreto finds a new home at Rigel Pharmaceuticals. Bristol Myers Squibb is focusing on diverse therapeutic options for cancer treatment, leveraging advanced modalities. GSK ends its collaboration with Vir Biotechnology on anti-influenza antibodies, and Indian drugmakers explore the weight-loss market with new products. Yearlybird Health launches a $186 million venture capital fund.Despite recent staff cuts at companies like Galapagos, Adaptive, and Ring, the industry continues to offer job opportunities at companies like Amgen, Novo Nordisk, Kerecis, Life Edit, Emergent Biosolutions, and Moderna. Stay tuned for more updates on the latest developments in the biopharma industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. AstraZeneca, the pharmaceutical company, recently had its day in court regarding a potential injunction on the Medicare drug pricing law. The outcome of the hearing will have significant implications for the healthcare industry. Meanwhile, Vertex Pharmaceuticals' non-opioid pain drug failed to outperform Vicodin in clinical trials, but experts believe that more can be done to develop effective non-opioid pain medications. In other news, a study has found that the Inflation Reduction Act's drug price negotiation program will have only a modest impact on global biopharma revenues and is unlikely to result in significant cuts to research and development. Sanofi reported a $600 million net loss in Q4 2023 due to various factors, despite strong sales of its blockbuster drug Dupixent. Additionally, Roche's 2024 strategy aims to combat low growth through pipeline cuts and mergers and acquisitions. Daiichi Sankyo has raised its sales forecast for Enhertu due to non-US growth, and the FDA Commissioner has highlighted adcomm reform, funding, and AI as priorities for the agency.Moving on to other industries, Pepsi is generating excitement for the Super Bowl with its "Get Wild" campaign for Pepsi Wild Cherry. Gatorade, another brand under PepsiCo, is launching a free membership platform to fuel its digital transformation. Jif, the peanut butter brand, is tackling "celery neglect" on game day by offering free peanut butter through a tie-up with Gopuff. In social media news, CEOs faced tough questions about child protection in a Senate session, with senators arguing that social platforms need to do more to protect young users. Advertiser Perceptions' Erin Firneno advises media companies on how to communicate brand momentum in 2024. The Super Bowl LVIII ads are being tracked, with reveals from Michelob Ultra and Paramount+, and teasers from Uber and Nyx. Google, CrowdStrike, and State Farm will also be returning with ads. Lastly, Marketing Dive's daily newsletter offers insights and news for marketing leaders.In the field of research, BioIVT is a leading provider of control matrices, offering biofluids, tissues, and matrices from commercial animals for research purposes. These biospecimens undergo strict quality control measures to enhance assay sensitivity. BioIVT offers a wide range of control matrices, including serum, cerebrospinal fluid (CSF), ocular fluid, and various tissues. These samples can be shipped fresh, cold, or frozen to ensure reliability and quality. Additionally, BioIVT provides matrices from commercial animals.Thank you for listening to Pharma and Biotech daily. Stay tuned for more important updates in the world of Pharma and Biotech.

Howie and Harlan are joined by Stephanie Sudikoff, an expert on using simulation to train healthcare professionals, to discuss her new venture working to expand treatment for neonatal jaundice and how simulating procedures can assist in quality control and ongoing training. They also look at new developments in AI in radiology and the economics of a powerful treatment for inflammation.  Links: AI and Radiology “Imaging AI hogs the spotlight at RSNA, with debuts from GE, Siemens, Philips” “Accuracy of ChatGPT, Google Bard, and Microsoft Bing for Simplifying Radiology Reports” “Characterizing the Clinical Adoption of Medical AI Devices through U.S. Insurance Claims” “Kim Kardashian Got a Full Body Scan, Why Medical Experts are Concerned” “Design goal: Photon Counting CT engineered with Deep Silicon technology to enable advanced CT Imaging” Heart Flow: Revolutionizing Precision Heart Care Neonatal Jaundice and Medical Simulation Little Sparrows Technologies: Big Ideas for Little Babies Stephanie Sudikoff: “Variability in quality of chest compressions provided during simulated cardiac arrest across nine pediatric institutions” “‘The Damar Effect'—the nationwide backorder on a lifesaving machine and the 620% increase in CPR” Stephanie Sudikoff: “An Approach to Confederate Training Within the Context of Simulation-Based Research” "Assessing the quality of primary healthcare in seven Chinese provinces with unannounced standardised patients: protocol of a cross-sectional survey" The Economics of Dupixent “Sanofi, Regeneron say Dupixent succeeds in another late-stage COPD study, setting up filing for FDA approval” “With new trial data, a blockbuster therapy from Sanofi, Regeneron could find an even bigger market” “A Drug for Itchy Dogs Costs $1,200. Why Is the Human Equivalent $43,000?” “Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts” Regeneron: “Dupixent ® (Dupilumab) significantly reduced COPD exacerbations in second trial” “HHS Selects the First Drugs for Medicare Drug Price Negotiation” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today we have some exciting news to share with you. Eli Lilly has recently entered into a collaboration with Tokyo-based Prism Biolab to develop small molecule inhibitors of protein-protein interactions. This partnership aims to target protein-protein interactions, which play a critical role in various disease processes. By developing drugs that can disrupt these interactions, there is potential for novel therapies for diseases such as cancer and autoimmune disorders. Lilly will be paying up to $660 million to gain access to Prism Biolab's proprietary platform.In another partnership, Boehringer Ingelheim has teamed up with Phenomic AI to develop targets for stroma-rich cancers. Stroma-rich cancers are known for their resistance to treatment, so by targeting the stroma, there is hope that the efficacy of cancer therapies can be enhanced. Boehringer Ingelheim will be paying $9 million upfront, with the potential for up to $500 million in milestone payments.Moving on to some interesting research, real-world data suggests that Eli Lilly's tirzepatide may achieve stronger and faster weight loss compared to Novo Nordisk's semaglutide in patients with type 2 diabetes. Healthcare analytics firm Truveta analyzed electronic health records and found promising results for tirzepatide.In regulatory news, the FDA has launched an investigation into malignancies linked to CAR-T therapies. The agency is evaluating the risk of T cell malignancies associated with CAR-T treatment and may take regulatory action if necessary.Shifting gears, we have some updates from the business world. Verve Therapeutics' stock price has recently dropped following a $148 million public offering. On a positive note, Novartis has raised its growth target as part of its "pure-play" strategy and has made adjustments to its pipeline.On a more global scale, a recent comparison of drug prices in the U.S. and other countries reveals significant variations, highlighting the complexities of pricing in the pharmaceutical industry.In our podcast section, we will be discussing recent deals in the industry, drug shortages for Dupixent and GLP-1 drugs, and the challenges faced by contract development and manufacturing organizations in 2023.Thank you for tuning in to Pharma and Biotech Daily. Stay informed, stay curious, and have a great day!

Howie and Harlan are joined by Stephanie Sudikoff, an expert on using simulation to train healthcare professionals, to discuss her new venture working to expand treatment for neonatal jaundice and how simulating procedures can assist in quality control and ongoing training. They also look at new developments in AI in radiology and the economics of a powerful treatment for inflammation.  Links: AI and Radiology “Imaging AI hogs the spotlight at RSNA, with debuts from GE, Siemens, Philips” “Accuracy of ChatGPT, Google Bard, and Microsoft Bing for Simplifying Radiology Reports” “Characterizing the Clinical Adoption of Medical AI Devices through U.S. Insurance Claims” “Kim Kardashian Got a Full Body Scan, Why Medical Experts are Concerned” “Design goal: Photon Counting CT engineered with Deep Silicon technology to enable advanced CT Imaging” Heart Flow: Revolutionizing Precision Heart Care Neonatal Jaundice and Medical Simulation Little Sparrows Technologies: Big Ideas for Little Babies Stephanie Sudikoff: “Variability in quality of chest compressions provided during simulated cardiac arrest across nine pediatric institutions” “‘The Damar Effect'—the nationwide backorder on a lifesaving machine and the 620% increase in CPR” Stephanie Sudikoff: “An Approach to Confederate Training Within the Context of Simulation-Based Research” "Assessing the quality of primary healthcare in seven Chinese provinces with unannounced standardised patients: protocol of a cross-sectional survey" The Economics of Dupixent “Sanofi, Regeneron say Dupixent succeeds in another late-stage COPD study, setting up filing for FDA approval” “With new trial data, a blockbuster therapy from Sanofi, Regeneron could find an even bigger market” “A Drug for Itchy Dogs Costs $1,200. Why Is the Human Equivalent $43,000?” “Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts” Regeneron: “Dupixent ® (Dupilumab) significantly reduced COPD exacerbations in second trial” “HHS Selects the First Drugs for Medicare Drug Price Negotiation”  Read an unedited transcript of this episode. Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

TAKE ACTION WITH DIANE KAZER & THE CHI TEAM —> JOIN MY VIP GROUP Only $7 for your first month: DianeKazer.com/VIP and get 50% off ALL Courses + 10% off ALL Supplements —> SHOP All Detox, Parasite Cleanse & Hormone Healing Supplements:  www.shop.dianekazer.com —> FREE Warrior Cleanse Module (also get on my email list): www.DianeKazer.com/FreeDetox —> Full Moon Parasite Cleanse FREE Module: www.DianeKazer.com/FMCFreeModule —> Book a call with Diane and the CHI Team: DianeKazer.com/call   FOLLOW DR DAVID NIXON'S WORK www.drdavidnixon.com   IN THIS SHOW, WE COVER: PFIZER C0Vid Shots - Proof of Borg technology & self assembling microorganisms Dental Anesthetics - are we at risk going to the dentist, especially the ones who are unaware of these toxic implications? BOTOX exposed - what Dr Nixon discovered under the microscope and what that means to your health What he found in other Injectables like Dupixent - prescriptions to ‘treat Eczema' which spiked post jabs (skin issues = parasite infections…this is what has been discovered under the miscope of the ‘shots') Are there any alternatives to these Injections? This is a bit of a heavy episode as we discuss truths that are not offered in the form of ‘Informed Consent' from the ‘professionals' in the Western Medicine community, so we are here to bring them to you and you can decide what to do from there. Dr David Nixon recently walked away from his medical practice of 25 years to pursue and disclose the truth of what is in these so called ‘vaxseens' and now has been on a mission to share what he's found in others such as Botox and other Western Medicine pharmaceuticals administered in IV form.   IN THIS EPISODE WE SHARE WHAT HE FOUND…   LINKS REFERENCED DURING THE SHOW: https://drdavidnixon.com//1/en/topic/about-me https://davidnixon.substack.com/p/comirnaty-sample-from-august-5th https://davidnixon.substack.com/p/comirnaty-sample-from-august-4th https://davidnixon.substack.com/p/comirnaty-sample-220802-as-seen-on https://davidnixon.substack.com/p/this-is-a-chip https://davidnixon.substack.com/p/construction-video-revised https://davidnixon.substack.com/p/borg-chip-2-re-visited https://davidnixon.substack.com/p/back-to-botox   FROM HIS WEBSITE: I graduated MB, ChB from the University of Otago in New Zealand in 1992. The purpose of this website is to share my observations and opinions with respect to the Covid-19 injectables. With respect to Colloidal Gold – trials haven't been conducted yet on people. The recent discussions are based on initial findings on a slide Clearly there has been a lot of things about the Covid-19 pandemic that hasn't made sense unless the events of the last three years are seen in a broader context and we consider other global agendas. It was never possible that we know that the Covid-19 injectables are safe in pregnancy, let alone effective and I am pleased to say that I actively always discouraged my pregnant patients not to have this medication. Clearly the official narrative was that these injectables were safe in pregnancy. As a medical professional I was constantly bombarded with this message from every official organization. And besides C0vid19 was such a threat during pregnancy that “you must have the vaccination” – really??? I became increasingly aware of the resounding unison of “there is nothing to see here” despite the number of groups and individuals who were posting concerning images online. So in mid 2022 I purchased a darkfield microscope and started looking at my own blood and that of patients. I also started looking at what we were injecting into people and I started voicing my concerns about what I was seeing.

This week we talk struggles with GLP-1 drug shortages and what that might mean for Novo/Lilly competitors; Regeneron and Sanofi positive results for ⁠⁠Dupixent⁠⁠ in COPD. Plus, Merck buys Caraway, Beigene's deal with Ensem, ups and downs for Flagship. Join BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen as they discuss the most important biopharma news this week.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Advocate Health experienced slower growth in the third quarter of 2023, although it remained profitable for the first nine months of the year. A review of the 340B drug discount program found mixed evidence on how hospitals use the funds. Some studies suggest that hospitals use the savings for purposes unrelated to patient care. Welltok, a patient engagement company, experienced a data breach in the spring that exposed the data of nearly 8.5 million people. Healthcare bankruptcies have increased in 2023 due to the expiration of federal COVID-19 funding, higher interest rates, regulatory changes, and labor shortages. The average per-worker cost of health benefits rose by 5.2% in 2023, with inflation and rising prescription drug costs being contributing factors. Hospitals are losing millions of dollars due to staff nurse turnover.Now let's move on to some exciting developments in the pharmaceutical industry. Regeneron and Sanofi are planning to seek new approval for their blockbuster drug, Dupixent, in the US after successful results from a phase 3 trial testing the drug in chronic obstructive pulmonary disease (COPD). The trial showed that Dupixent could reduce attacks and improve lung function in patients with the respiratory condition. Meanwhile, GSK's cancer drug Blenrep has received a surprise trial win. The drug was withdrawn from the US market last year due to negative data, but new study results may open the door to a relaunch. Xenon's depression drug, Xen1101, missed the main goal of a mid-stage trial. However, the company believes there were enough positive findings to warrant further study of the drug in depression. Novo Nordisk is planning to expand its French plant in a push to increase production of GLP-1 drugs. These developments come as dozens of cell and gene therapies are expected to receive FDA approval in 2024, leading to a need for enhanced patient access and cost management strategies.In other news, GlaxoSmithKline (GSK) is looking to bring back its antibody-drug conjugate Blenrep for the treatment of relapsed/refractory multiple myeloma. A year after withdrawing the drug from the US market, GSK has presented promising Phase III data that supports its potential comeback. The results showed that Blenrep, when used in combination with other therapies, significantly improved progression-free survival compared to standard of care alone. GSK plans to submit the data to regulatory authorities for review. Novo Nordisk is warning the EU of potential shortages of its GLP-1 drugs and is expanding production at its French site to meet the high demand for its drug Ozempic. 89bio has unveiled bullish long-term data for its nonalcoholic steatohepatitis (NASH) candidate pegozafermin. The drug showed statistically significant improvements in treating patients with NASH, positioning it as a potential treatment option for the condition. Overall, these developments highlight GSK's potential comeback with Blenrep, Dupixent's efficacy in COPD, Novo Nordisk's efforts to meet high demand for Ozempic, and 89bio's progress in developing a treatment for NASH.That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more updates in the world of Pharma and Biotech.

Le CAC 40 a voisiné son seuil d'équilibre une bonne partie de la séance avant de céder en fin de séance pour clôturer à -0,37% vers les 7.265 points et 2,2 milliards d'euros échangés. Un indice qui hésite désormais sur la direction à suivre après avoir regagné plus de 5% en un mois et aligné trois séances de hausse en fin de semaine dernière.C'est d'ailleurs un peu la même ambiance de l'autre côté de l'Atlantique, au sortir d'une semaine réduite à Wall Street. A 17h45, le Dow Jones recule de 0,2% et le Nasdaq est proche de son point d'équilibre, autour de 12.265 points.Dans l'actualité, un grand nombre de responsables de la Fed doivent s'exprimer cette semaine et les investisseurs attendent également la publication du "Livre beige" ainsi que l'indice PCE des prix à la consommation pour octobre.Valeurs en hausseLes foncières sont à nouveau à l'honneur, à l'image d'Argan ou Gecina sur le SBF 120 ou d'Unibail-Rodamco-Westfield.X-Fab Silicon se distingue également. Elior a toujours faim de hausse : +57% sur 1 mois et +1,42% aujourd'hui. C'est Deutsche Bank qui se ressert. Le bureau d'analyse de la banque allemande est passé de "conserver" à "acheter" avec un objectif de cours fixé à 3,40 euros.Sur le CAC 40 en plus de URW, Orange, Engie et L'Oréal grimpent également tout comme Sanofi. Le groupe pharmaceutique veut demander l'autorisation aux Etats-Unis d'utiliser le Dupixent, son anti-inflammatoire le plus vendu, dans le traitement de la BPCO. A l'appui de cette demande, un deuxième essai de phase 3 a montré que le médicament réduisait les exacerbations de la maladie de 34%.Valeurs en baisseToujours très animé le cours d'Orpea s'inscrit en baisse de 12%Début de semaine compliqué pour Atos. Selon BFM TV, le groupe de services informatiques a entamé des négociations pour revoir les termes de son accord avec Daniel Kretinsky pour la vente de ses activités historiques. Ce dernier ne sera finalement pas actionnaire d'Eviden, la branche dédiée notamment à la cybersécurité et aux supercalculateurs. Atos aurait en effet finalement renoncé à une telle option face au refus de certains élus et de fonctionnaires du ministère des Armées compte tenu du caractère souverain de ces activités.Euroapi et SES Imagotag sont également sous pression.Sur le CAC 40 Thales et LVMH signent les plus forts replis. LVMH qui recule désormais de 15% sur six mois.Les banques sont aussi sous pression à l'image de BNP Paribas ou Société Générale

The God & The Greatboy are back in studio for another splendiferous episode of NNFA. We reminisced about the pandemic, did a deep dive on Derek's eczema and how the Dupinxet commercial worked on him, we asked why we can't eat Eagles and so much more! This is No Need for Apologies!-----------------HOW TO HELP US GROW:1. Like this and every video2. Comment for the algorithm 3. Subscribe to NNFA on YouTube4. Listen & Subscribe on Apple Podcast & Spotify or anywhere you listen to podcasts5. Review and Rate all 5 stars!6. Share with friends & on Social Media "Hey check out this podcast?!"7. Buy NNFA Merch8. Subscribe to NNFA on GasDigital.com/NNFA using promo code “NNFA”9. Follow Dave & Derek on social media10. Come back Next week and Repeat!-----------------FOLLOW NO NEED FOR APOLOGIES!The Hosts:Derek GainesIG - https://rb.gy/3okmfe Twitter - https://rb.gy/ovoex8 Dave TempleIG - https://www.instagram.com/imdavetemple/ Website - https://www.davetemplecomedy.com/ The Podcast:No Need For Apologies IG - https://www.instagram.com/nnfapodcast/ TikTok - https://www.tiktok.com/@nnfa.podcast Production:Producer - Teona Sasha IG - https://www.instagram.com/teonasasha/ TikTok - https://www.tiktok.com/@teonasasha?lang=en Engineer - JorgeEdited By - Rebecca KaplanIG - https://www.instagram.com/rebeccatkaplan/ TikTok - https://www.tiktok.com/@rebeccatkaplan?lang=en -----------------WANT THE FULL CATALOG? Go to https://gasdigitalnetwork.com/NNFA Use Code: “NNFA” for a 7-day free trial on the entire GaS Digital subscription.Gain access to all things NO NEED FOR APOLOGIES - ALL of the episodes, uncensored, in Full HD, AND a week earlier! -----------------To advertise your product on GaS Digital podcasts please email jimmy@gasdigitalmarketing.com with a brief description about your product and any shows you may be interested in advertising on.SEND US MAIL:GaS Digital StudiosAttn: NNFA151 1st Ave # 311New York, NY 10003“NNFA” is a GaS Digital Production. New Episodes drop WEDNESDAYS on GaS Digital for subscribers ONLY and SUNDAYS & TUESDAYS for limited release on YouTube.-----------------#NoNeedForApologies #NNFA #DerekGaines #DaveTemple #Comedy #Podcast #ComedyPodcast #GasDigitalNetwork #NNFAPodcast #NoNeedForApologiesPodcast See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Bradley shared his journey of overcoming eczema through holistic means, including dietary changes and lifestyle adjustments. He outlined his daily routine, which included a predominantly meat-based diet, occasional fruits, sauna use, regular exercise, and a visit to the ocean. Bradley also shared his experiences with autoimmune disorders, topical steroid withdrawal, and his refusal of a new drug, Dupixent, due to its potential side effects. He emphasized the legitimacy of leaky gut as a real condition despite some medical professionals' discrediting it. Moreover, Bradley expressed his excitement about expanding his horizons through writing. He advocated for a natural healing process and distrusted big pharmaceutical drugs. He also discussed his concerns about nutrient deficiencies in a lion diet and the benefits of an animal-based diet. Bradley's dietary views seem to be contentious, with some viewers supporting his stance and others warning against it.

Dermatopathology isn't typically meant to provide definitive diagnosis. But it can give important information for supporting a diagnosis and guiding patient care. Michelle Hure, MD, founder of OC Skin Lab in Orange County, CA, shares 10 tips for getting better results from a dermatopathologist. Also in this edition, Michelle Sullentrup of MyDermRecruiter.com talks about measuring production and David Cohen, MD, MPH talks about when and how to suspect dupilumab failure.Like what you're hearing? Have a topic you want to hear more about? Hit us up and spread the word on Instagram!

Dupixent has transformed the lives of people with moderate to severe eczema, but will patients need to use it indefinitely? In this episode we explore tapering Dupixent (also known as dupilumab) with two researchers from University Medical Center Utrecht in the Netherlands that have created a patient-led roadmap for successful tapering. They are: Pediatric Dermatologist Dr. Marlies de Graaf, Head of the National Expertise Center of Atopic Dermatitis in Children; and Dr. Celeste Boesjes, who is a PhD candidate and Medical Doctor.Research Discussed in this PodcastSuccessful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registryAssociation of serum dupilumab levels at 16 weeks with treatment response and adverse effects in patients with atopic dermatitis: a prospective clinical cohort study from the BioDay registryPatient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitisDupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registryDupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis

We discuss the theatrical merits and actual implications of Moderna CEO Stéphane Bancel's appearance before a committee led by Sen. Bernie Sanders. We also talk about the latest news in the life sciences, including Regeneron Pharmaceuticals' latest data for its powerhouse drug Dupixent, an about-face for Sarepta Therapeutics, and how the FDA appears to view biomarkers in neurological diseases.

Today, it's all about the eyes, which are somewhat the extension of our brain, so treating ANY condition with them can be scary. I've gotten a lot of questions from listeners about dupilumab (Dupixent) and the side effects specifically when it comes to the eyes. So to dive in on this topic, I brought in today's guest, Dr. Roselie Achten, since her PhD focuses on ocular surface disease in atopic dermatitis patients before and during dupilumab treatment. Dr. Roselie Achten is a medical doctor and PhD student at the Department of Dermatology at the University Medical Center Utrecht in the Netherlands, and I am so excited to have her on the show! You can find some of her research findings in the links section below. Have you ever experienced any side effects with your eyes after starting dupilumab? I'd love to hear about it in the comments! In this episode: Stats on how many patients develop Dupixent eye side effects (aka. dupilumab-associated ocular surface disease) Eye symptoms of patients commonly complain about How long does it typically take to develop eye problems from Dupixent? What puts you more at risk for developing Dupixent eye side effects? What are your options if you develop Dupixent eye side effects? Can reducing the use of Dupixent help? Quotes “We were also quite surprised by the fact that the majority of the patients with moderate to severe atopic dermatitis already had characteristics of the ocular surface disease. So of the 70 patients that were analyzed, 90% of them already had characteristics of ocular surface disease before the start of Dupilumab treatment." [11:09] "If patients have these signs and symptoms of dupilumab associated ocular surface disease, we first start with tacrolimus skin ointment for the external eyelids. We also start with ketotifen, which is an antihistamine eye drop... also the artificial tears, it's more for if you experience a dry eye sensation, it could lead to improvement of that symptom for a little time." [17:12] Links Find Dr. Roselie Achten online here Healthy Skin Show ep. 244: How Do Biologic Drugs For Chronic Skin Conditions Work? w/ Heather Zwickey, PhD Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis - ScienceDirect Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis - PMC (nih.gov) Ocular surface disease is common in moderate to severe atopic dermatitis patients - Achten - 2022 - Clinical & Experimental Allergy

Briana is a TSW warrior as well as a woman who wears many hats! She is responsible for the filming, editing, creating, producing, and more, for the wildly successful and popular TSW documentary, Preventable (which you can watch here). Briana shares with us her TSW journey and what led her to embark on the arduous task of making her documentary film. She opens up about her hair loss, the pure exhaustion, the medications and her hopes for the future. Life Update: Briana is currently taking Dupixent to help with her flare ups and is sharing her experience on her social media platforms. She is also currently working on a documentary sequel - Still Preventable! To purchase your very own TSW Journal - click here! ----------------------------------- ⭐️ LET'S CONNECT WITH ONE ANOTHER!

Après un démarrage dans le rouge, le CAC 40 s'est finalement décidé à aller de l'avant, porté par des publications d'entreprises. Le CAC 40 termine la séance sur une hausse de 0,46% vers les 6273 points. Du côté des valeurs, Airbus a pris la tête du CAC 40 et gagne 3,46%. Le groupe a révélé des résultats solides sur les 9 premiers mois de l'année. Sanofi avance de 3,25%. Le laboratoire français a revu à la hausse ses perspectives pour 2022 après avoir réalisé des ventes en nette croissance au troisième trimestre. Des ventes toujours dopées par son médicament phare Dupixent mais aussi par les vaccins. En troisième position on retrouve Danone qui gagne 2,9% après avoir relevé ses objectifs financiers pour l'année en cours. Le géant de l'agroalimentaire a enregistré une forte progression de son chiffre d'affaires au troisième trimestre tiré par la hausse des prix. A l'inverse, ST Micro est toujours sanctionné par les marchés : -2,22%. Pour rappel, le groupe anticipe un ralentissement de la croissance de ses ventes au cours de la dernière partie de l'année. De son côté, Renault perd 1,54%, plombé par les mauvais résultats de Volkswagen. Sur le SBF 120, Safran s'offre une progression de 2,38%. Le motoriste a publié un chiffre d'affaires de 5 milliards d'euros réalisé entre juillet et septembre, en progression de presque 30% par rapport à la même période de 2021 A l'inverse, gros trou d'air pour Air France-KLM, plus de 13 %. Pourtant, le groupe a vu ses résultats bondir sur la période allant de juillet à septembre, bénéficiant de la forte demande des touristes. Mais les analystes se montrent sceptiques et pointent des comptes encore fragiles. D'autant que le groupe a abaissé ses prévisions pour le quatrième trimestre. Grosse chute également pour Solutions 30. Tout comme Orpea qui n'en finit plus de dégringoler. Enfin, on termine par les marchés américains. Après Meta, c'est au tour d'Amazon de décevoir. Le groupe s'attend à un ralentissement de la croissance de ses ventes sur les derniers mois en raison de la dégradation du pouvoir d'achat des consommateurs. En attendant au moment de la clôture les 3 indices de la Bourse de New York évoluent dans le vert. Le CAC 40 termine la séance sur une hausse de 0,46% vers les 6273 points.

  Vidcast:  https://youtu.be/Av2ePEF8L3w   For the first time, a biologic drug relieved the nagging itch of moderate-to-severe eczema for babies and preschoolers.  The monoclonal antibody dupilumab, better known to TV audiences as Dupixent, drives a 75%+ reduction in eczematoid itch and better sleeping in at least half the children 6 months through 5 years who took it for 4 months.   These findings come from a Northwestern University-led Phase 3 study of the drug in 162 kids 6 months to 6 years of age at 31 sites across North America and Europe.  The drug has already been approved for older children, teens, and adults with eczema.   https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01539-2/fulltext   #eczema #dupixent #itch #sleep #infants #toddlers  

Welcome to the Less Stressed Life, where we help women and families overcome fatigue, food sensitivities and inflammation the goal here is really to help you heal yourself.  If this you find this show or episode helpful, repay the favor and share it with a friend or leave me a review on the purple pod app if that's where you listen. Leave us a review: https://reviewthispodcast.com/lessstressedlifeYou can submit your own questions or case for review @ https://www.christabiegler.com/questions In this episode I answered listener questions from Mary and Jordan:  Mary is wondering about parasite testing and symptoms of moodiness, poor sleep, loose bowels, hair thinning, dry skin and frequent post nasal drip. CASE REVIEW: Jordan gives us a little more information and shares her case in more depth: History of eczema throughout my whole life, but only on arms and legs. Have had since I was a child. Presented as red, itchy bumps on legs and back and as flaky and itchy red patches in creases of elbows mostly during summer)Started having Increased flares starting in summer of 2020 with itchy bumps and red patches covering most of body. Additionally, developed new type of severe eczema on my face, neck, hairline that had never occurred before. Before this, had never had any eczema on my face. Flares got increasingly worse over the next ~6 months.Dermatologist gave 10 day taper of oral prednisone and topical steroids to help "heal eczema (Jan 2021) and then started on Dupixent (injections every other week). Stopped injections in Feb 2022.After stopping injections had small amount of eczema on body, only small itchy bumps, nothing on face.  Face had another severe flare in July-August 2022 requiring topical steroids to heal again.Additionally, only have 3-4 BMs per week. Do not use any stool softeners/laxative. (but uses motility support!)Feeling very fatigued in the afternoons, trouble getting out of bed in the mornings for a long time. New issues of waking up in the middle of the night and occasional muscle cramping.Saw functional MD who did blood work and Gut Zoomer stool test (Vibrant wellness).Stool test with gut commensals high for leaky gut, moderate for SIBO and other categories. Low for cardiovascular health and IBD. MD gave supplement regimen and SIBO diet for 30 days.  Abnormal labs: OmegaCheck 3.0 (low), AST 31 (high), Vit D 33.4, B12 246Current supplements: Magnesium citrate, Motility Pro, SBI protect, Atrantil; have been taking for 2 weeks, no supps before this.  controlJordan also asked: Do you have specific probiotics you recommend?How to get away from relying on long-term supplement use for regular bowel movements (currently taking 450mg Mg each night, Atrantil, and Motility- pro)What is your experience with using Low Fodmap or a SIBO diet for healing your gut/have you seen them be successful in the long-term with people able to add most foods back in?I also give a bit of context to different ways you can look at an issue with the "healing triad". WHERE TO FIND CHRISTA:https://www.christabiegler.com/On IG:instagram.com/anti.inflammatory.nutritionist/Shop our Favoriteschristabiegler.com/shopAre you a practitioner curious about labs?A special thanks to our VIP sponsor RUPA Health, our lab concierge service that helps our clients get standard bloodwork 2/3 off retail direct to consumer lab test pricing. Let them know I sent you w

Dr. Ana-Maria Temple is a holistic pediatrician, best-selling author, mother of 3, and award-winning speaker. In this episode, she shares what eczema is and how to prevent and cure it. She also speaks about the dangers of mold toxicity and how to start the process of food elimination. Just when we think we know about the boundaries of ADHD, we get reminded that it can expand to other different types of illnesses in the body.   Skin health is just as important as brain and gut health because our skin is an external reflection of our inner body. Healing the skin starts with healing the gut and the brain. Tune in to find out more about eczema and find ways to fight and prevent it!     Key Takeaways: [3:38] What eczema is and how it is correlated with ADHD [6:33] Prescribed medicine for eczema [12:35] Quebec Ice Storm study [14:40] The condition of the skin is a reflection of the condition of the gut [22:24] Detrimental effects of mold on the skin and lungs [28:28] There is no simple solution to curing eczema     How To Connect With Dr. Temple: Website: https://www.dranamaria.com/ All socials: Dr. Ana Maria Temple     Memorable Quotes: “Eczema is usually red, patchy… it looks like flame, it looks like red hot lava (I'm a pediatrician, so I talk in kid terminology). A lot of times in babies, we'll see their cheeks be red hot lava… eczema is when those red cheeks don't go away and they get worse and worse.” “Now we're eating strawberries and now the red cheeks are flaring even more, now we're eating bananas and avocado (and I'm not beating up on food, I'm just giving examples). And then all of a sudden, the redness from the cheeks is now red hot lava neck.”  “We have kids that have dry skin but it's not just dry skin. It's dry skin and then they sit and they scratch and they dig and they have trouble sleeping at night and they're crying throughout the day. It seems whatever they eat, they flare up. They go outside, they flare up.” “I get very weary because a lot of the prescribed medications are topical steroids, oral antibiotics, and of course, the latest and greatest, Dupixent - and I say that with a lot of sarcasm.” “Modern medicine does work for some people but we're talking ‘some people,' and turning it into all people… we do not have this much data on this medication; we do not know the long-term effects of Dupixent.” “What a lot of people don't know is that the medications that are linked to the increased appearance of eczema is actually Tylenol. We give babies Tylenol and it's no big deal… Teething is overly diagnosed by the parents because they want to put a name to the fussiness. And then they're like, ‘Let me give them Tylenol.' Tylenol is sugar and food dyes.” “They took the pregnant ladies that were displaced in the ice storm and these mamas had to live with cousins and uncles… and they compared these moms to other pregnant moms in Canada. They followed them around for 15 years and they looked to see what was the endpoint? Did anything happen to their children? And they saw an increase in ADHD, neurological developmental issues, delay in neurocognitive function, speech delays, verbal delays, autism, eczema, asthma, diabetes, and cancer.” “Without healing the gut, paying attention to what's in your child's diet, in your own diet if you're nursing, it is very difficult to cure the skin with just a cream.” “I'm not saying no to processed foods. It's how much are you really having and then we're going to turn those around and read the ingredients. If you can't read it, don't eat it.”     Dana Kay Resources:    Website - https://adhdthriveinstitute.com/ Facebook - https://www.facebook.com/adhdthriveinstitute  Instagram - https://www.instagram.com/adhdthriveinstitute/  YouTube - https://www.youtube.com/c/ADHDThriveInstitute  LinkedIn - https://www.linkedin.com/company/74302454/  Pinterest - https://www.pinterest.com/adhdthriveinstitute/ Tiktok - https://www.tiktok.com/@adhd_thriveinstitute     International Best Selling Book, Thriving with ADHD - https://adhdthriveinstitute.com/book/    Free Reduce ADHD Symptoms Naturally Masterclass - https://adhdthrivemethod.com/masterclass-rego-page     ADHD Parenting Course - https://adhdthrivemethod.com/adhd-thrive-jump-start-parenting-4-adhd    ADHD Thrive Method 4 Kids Program - https://adhdthriveinstitute.com/packages/

Mark Singer 58, anaplastic thyroid cancer, Barrington, RI   In the early stages of the pandemic, Mark knew something was wrong when he noticed a small lump on his neck. Soon after, he went to an ER for testing and received a diagnosis of anaplastic thyroid cancer, a very serious form of the disease which prior to 2017 had a one-year survival rate of 10% -20%.  After Googling “Best Cancer Hospitals in New England,” Dana-Farber moved to the top of his list for care. Mark started with a year of immunotherapy treatments with Nivolumab, also known as Opdivo, and Dupixent, which he still currently takes, for any side effects. Immunotherapy is a new cancer treatment that allows the body's own immune system to recognize and kill cancer cells.  Mark had a rapid and profound response and has shown no evidence of disease for over a year. In addition to immunotherapy, his care team was able to remove a cancerous tumor from his thyroid, several cancerous lymph nodes, and perform vocal-chord repaire surgery.  Today, Marks feels mostly back to his pre-cancer self. You can find him boating around Lake Winnipesaukee or riding on his Harley-Davidson motorcycle. He's supported by his wife, Mary, and their two children, Michael and Maggie. 

Novavax Emergency Use authorization; the Pfizer-BioNTech vaccine gets approval in adolescents; submission for oral contraceptive to be switched to over the counter; Astepro nasal spray gets over-the-counter approval; and Dupixent shows benefits in pediatric patients with eosinophilic esophagitis.

If you've ever dealt with a skin rash like eczema, you know the itch and the feeling of embarrassment or anger perhaps. Now imagine being the center of attention as a pageant queen being partially judged on how you look and carry yourself. Today's guest had to figure out how to navigate her journey with eczema all while competing in pageant after pageant. Abby Cramond is a junior at Louisiana State University majoring in Digital Advertising and minoring in Textiles Apparel and Merchandising. She is a digital creator and entrepreneur who manages multiple businesses' media pages and the owner of her own jewelry boutique. Abby wants to share her journey with eczema, not only to spread awareness, but to make others feel comfortable in their own skin and that they are not alone. Join us as we chat about her very personal, inspirational journey with eczema, all while being in the spotlight. Have you struggled with finding the true cause of your skin condition but finally found peace or found help in some way? Let me know in the comments! In this episode: Abby's eczema journey Various medications Abby tried with her doctor Her personal advice to get through the mental anguish The ONE thing that has worked so far in helping her eczema How Abby's standard of "what is beauty" has changed Quotes “...It's not the fact that you have eczema and then you just put the thing (on) they give you and it goes away. It's this never-ending process of finding out what product works best for you and what truly kills a problem at the core.” [1:16] “After the steroids, we were like, 'I can't be using cream anymore. There has to be another option.' So we went to the dermatologist and they're like, 'All right, we have this thing called Dupixent,' and listed, gave the whole rundown of it all. And I was like, I'm so desperate, I do not care what I need to do. So I gave it a shot, and it's the only thing that has worked for me so far.” [14:04] Links Follow Abby on Instagram| TikTok | Twitter Healthy Skin Show #050: How To Help Kids With Eczema w/ Dr. Sheila Kilbane Healthy Skin Show #098: Why Hope Is So Important When It Comes To Eczema (And How To Find It) w/ Camille Knowles Healthy Skin Show #151: How Eczema Changed My Life (So I Could Help Others) w/ Rakhi Roy, MS, RD, LDN Healthy Skin Show #230: {RESEARCH} Mindfulness Stress Reduction Benefits For Chronic Skin Problems Like Eczema + Psoriasis w/ Jessica Maloh

The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments.

Vidcast:  https://youtu.be/V4K0AKnztjM   Here are the quickie reports about cutting edge medical and healthcare discoveries this 1st week of June, 2022.   A new Swiss perfusion technique keeps donor livers alive and well for up to 3 days while they await transplantation into recipients.  In the past, the liver would only tolerate a 12 hour maximum residence outside the human body.  The additional time allows transportation for longer distances as well as the laboratory and tissue testing necessary to assume a good match and long-term function.   https://www.nature.com/articles/s41587-022-01354-7     From NY's Rockefeller University comes the news that a new synthetic antibiotic called cilagicin capably neutralizes even the nastiest, drug resistant bacteria including MRSA and C. difficile.  The drug is based on a computer prediction regarding the type of molecule a bacterium would create to protect itself from its more aggressive cousins.  Cilagicin works effectively by combining 2 molecules that together irreversibly weaken bacterial cells walls.  Existing antibiotics have only one such molecule.  The drug works in mice and is non-toxic to humans.   https://www.science.org/doi/10.1126/science.abn4213   A spoon full of sugar……. You know the rest.  MIT bioengineers and Harvard gastroenterologists have a better way to make the medicines go down for those with difficulties swallowing, say after a stroke, or an aversion to pills and capsules as do most kids.  Their better mousetrap is a gel-based drug delivery platform using gels composed of plant-based oils including sesame oil.  The gels can be produced with different viscosities and flavors.  Clinical studies are slated to begin soon.   https://www.science.org/doi/10.1126/sciadv.abm8478     The FDA has announced the first drug approved for the treatment of eosinophilic esophagitis.  The drug is dupilumab and its better known as Dupixent.  Its now approved for use in adults and teens 12 years and over weighing at least 88 pounds.  Eosinophilic esophagitis is a chronic inflammation that triggers swallowing problems with food trapping on the way down to the stomach.  Dupixent is about 60% effective in reducing the eosinophils populating the esophagus and driving this disorder.  No word yet on insurance coverage.   https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-eosinophilic-esophagitis-chronic-immune-disorder       There you have the latest health reveals for the 1st week of June, 2022.  When additional information about these developments becomes available, I'll pass it on to you.     #liver #transplantation #perfusion #bacteria #antibiotic #drugresistant #ai #swallowing #gels #stroke #plantoil #esophagitis #eosinophil #dupixent    

Ukoniq, a treatment just approved last year, has been withdrawn; We rundown a host of drug pipeline news in asthma, dermatology and oncology; and there's positive results for a novel postpartum depression treatment.

Host Ryan Piansky and co-host Mary Jo Strobel, talk with guest Dr. Amal Assa'ad about aeroallergens, food allergies, and eosinophilic esophagitis. Dr. Assa'ad is a pediatric allergist. She is a Professor at the University of Cincinnati in the Department of Pediatrics, as well as the Director of Clinical Services and Associate Director of the Division of Allergy and Immunology at Cincinnati Children's Hospital Medical Center. She is an accomplished, award-winning researcher who has published more than 100 peer-reviewed manuscripts and book chapters. In this episode, Mary Jo and Ryan invite Dr. Assa'ad to share her academic path and the research she has done on eosinophilic esophagitis (EoE) as well as current research directions. Dr. Assa'ad discusses how environmental allergens and EoE connected and why treatments for allergies are ineffective at preventing EoE. She also discusses a study on the demographic differences in the diagnosis of EoE and shares her optimism for biological treatments in the pipeline for eosinophilic disorders.   Disclaimer: The information provided in this podcast is designed to support, not replace the relationship that exists between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.    This podcast was recorded prior to the FDA approval of DupixentⓇ for indicated treatment of eosinophilic esophagitis for people aged 12 and older.   Key Takeaways: [1:11] Mary Jo introduces today's guest, Dr. Amal Assa'ad, Professor at the University of Cincinnati's Department of Pediatrics, Director of Clinical Services, and Associate Director of the Division of Allergy and Immunology at Cincinnati Children's Hospital Medical Center.   [1:45] Dr. Assa'ad is an accomplished award-winning researcher. Dr. Assa'ad has published over 100 peer-reviewed manuscripts, book chapters, and research publications. She holds several committee appointments and is an engaging speaker with a gift for teaching difficult concepts in an easy-to-understand way.   [2:29] Dr. Assa'ad is not college-educated! In Egypt, she went directly from high school to medical school. She is the first medical doctor in her family. She wanted to relieve patient suffering and study medical disorders. She started medical school at age 16 and stayed for seven years. At the age of 23, she was a physician.   [3:40] After receiving her MB BCh medical degree, Dr. Assa'ad entered a Master's program for a degree in testing for food allergies. In the United States, Dr. Assa'ad did a visiting fellowship in San Antonio, Texas, and an internship and residency in pediatrics in Michigan and Dayton, Ohio.   [4:38] From there, she joined Cincinnati Children's Hospital where she started her work in food allergy and other allergic disorders. She developed an interest in eosinophilic disorders. Dr. Assa'ad was always thrilled to be making science. With other doctors, she worked on several of the initial clinical trials for hypereosinophilic syndrome patients.   [5:51] From these trials, Dr. Assa'ad learned how patients present differently; at different ages, different organ systems affected, and with different quality of life.   [6:07] Dr. Assa'ad started working with eosinophilic esophagitis and eosinophilic gastroenteritis and contributed to the descriptions of these disorders and the study of the pathogenesis, presentations, and epidemiology. She continues to be very interested in the overlap of these disorders with food allergy and environmental allergy.   [6:55] Is EoE always triggered by food? Patients usually say if they take certain foods, they have symptoms that are associated with EoE. The symptoms of EoE are also very difficult to pin down. With infants, the symptom is feeding difficulties. In toddlers, it is vomiting. At school age, stomach aches. In adults, dysphagia, or difficulty swallowing.   [8:52] Quite often, EoE is not diagnosed until a major event happens, like a food impaction, like something getting stuck in the esophagus at dinner. Is it that the food instantly made the EoE worse, or is it the texture issue and the difficulty in the motility of the esophagus that cause the impaction?   [10:09] Are foods the only thing that can increase your EoE symptoms? What about environmental allergens that can contribute? Dr. Assa'ad cites a study in mice where allergens were put into the esophagus or the nose. The observation was that inhaled allergens may cause symptoms to worsen.   [11:00] Patients have been observed with symptoms that cycle with the seasons. Certain seasons were associated with either diagnosing EoE or flare-ups of EoE. There are common proteins between pollen and foods, so the question is: Are these kinds of proteins, whether in foods or inhalants, causing a flare-up of symptoms?   [11:57] When you have a flare-up of symptoms, you assume that you have a worsening of the pathology in the esophagus, so you have more eosinophils. Of course, you don't get an endoscopy every season, but you could assume the esophagus isn't working as it should.   [12:25] Dr. Assa'ad thinks that EoE is multifactorial. Different patients have different triggers. In the 1990s, when EoE was being described, researchers did skin tests for environmental and indoor allergens. In Dr. Assa'ad's published research, some EoE patients had no or few allergies, and others had many reactions to allergens.   [15:38] Dr. Assa'ad believes that patients with large numbers of allergies are patients who are likely to develop eosinophilic esophagitis because they tend to be allergic. She believes that the lining of the esophagus is primed and prone to respond to these food and environmental allergens. [16:14] How can you determine which foods are problematic for your EoE? Dr. Assa'ad describes the difference between sensitivity and allergy. Many studies were looking for connections between food sensitivities and EoE. Researchers used to try drastic dietary elimination, but now they limit the eliminations to a few foods.   [18:29] In a new study, not yet published, removing a few foods can significantly reduce the EoE symptoms. Some patients know that if they eat a certain food they are going to have symptoms, so they don't eat it. But don't restrict your diet to extremes. Maintain a good quality of life.   [20:50] What about seasonal EoE flare-ups? Is that only related to airborne allergens? There are no definitive population studies on this question. It is also very hard to filter out airborne allergens. But what other changes in the environment may cause EoE flare-ups during these cycles? They may be pollution, toxins, dust, and particulates.   [23:15] Dr. Assa'ad was surprised in her research by the number of positive tests she found in the larger part of the patients, who were highly sensitized to a large number of things. These patients were being treated for their symptoms and still got diagnosed with eosinophilic disorder. They were not being treated for the immunologic mechanism.   [24:16] Dr. Assa'ad was excited about a study where they looked at mepolizumab in eosinophilic disorders. The study showed it did decrease the eosinophils in the biopsies but it didn't meet the primary goal endpoint of ameliorating symptoms, which is something that has plagued a lot of the eosinophilic disorders studies.   [25:39] These study patients came having already had treatments for allergies but they still developed the disorder. Mepolizumab went on to be developed for eosinophilic asthma and eventually for hypereosinophilic syndrome as well, but not for eosinophilic esophagitis or gastroenteritis. Dr. Assa'ad is hopeful it will be developed for EoE.   [26:41] Dr. Assa'ad recommends patients with EoE symptoms that are caused by environmental allergens to treat the allergic symptoms. It's important for patients to manage their quality of life.   [28:28] It has been noted that epidemiologically, eosinophilic esophagitis and the disorders are more common on the east and west coasts but less common in the middle of the country. Is it the stresses and rapid pace of life on the coasts?   [29:38] Dr. Assa'ad has seen improvement with puffed and swallowed fluticasone. They have published papers on that.   [30:25] The availability of endoscopies and biopsies in the United States is far greater than in other countries, even European countries. The diagnosis of EoE in some countries relies on counting eosinophils in blood samples instead of biopsies. Flare-ups and eosinophil counts do not necessarily correlate. Other countries go by symptoms.   [32:21] Environmental allergens are very different in different countries so the influence of environmental allergens on EoE from country to country cannot be easily compared.   [33:13] What research is next for Dr. Assa'ad? Food allergies and working with colleagues at other institutions on a grant following a cohort of situationally diverse African-Americans and Caucasians with food allergies. They are looking into the diagnosis of eosinophilic esophagitis and how being diagnosed has differed by race.   [34:26] Through this cohort, they have found that EoE is infrequently diagnosed in African-American or Latinx populations that have symptoms that are very consistent with EoE.   [34:45] Dr. Assa'ad is also working on looking at the genetics of food allergies with regard to races and what makes a difference. She is also working on establishing a biobank for food allergy biomarkers for researchers around the country.   [36:04] Another project Dr. Assa'ad is working on is immunotherapy for food allergies. Patients with EoE have previously been excluded from studies with immunotherapy because it might provoke the disorder.   [37:30] Dr. Assa'ad focuses on where the patient is coming from and the patient's wants and needs. She is working on clinical trials with biologics and is optimistic about the results with acute food allergies and eosinophilic disorders.   [38:07] Mary Jo thanks Dr. Assa'ad for taking the time to talk with us.   [38:16] Dr. Assa'ad shares the optimism that the whole scientific community is making strides. A lot is coming down the pike and things are going to get better from the diagnostic and therapeutic points of view and improving the patients' quality of life and possibly helping other countries.   [39:19] Ryan invites listeners to look at apfed.org for additional resources to help with the day-to-day management of EoE. Ryan also encourages you to connect with the APFED online community and listen to past podcast episodes.   [39:59] Dr. Assa'ad thanks Ryan and Mary Jo for having her on the podcast and thanks APFED and other patient organizations.   Mentioned in This Episode: American Partnership for Eosinophilic Disorders (APFED) APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Amal Assa'ad, M.D. University of Cincinnati Cincinnati Children's Hospital Medical Center Food Allergy Research and Education (FARE) NIH apfed.org/eoe APFED EOS Connections Online Community APFED Podcast Episode Featuring Dr. Gupta   This episode is brought to you thanks to the support of our Education Partners Abbott, Bristol Myers Squibb, GlaxoSmithKline, Mead Johnson Nutrition, Sanofi, and Regeneron.   Tweetables:   “I was always very thrilled to be in a room where we are making science. We are making observations on these eosinophilic disorders and specifically, eosinophilic esophagitis and hypereosinophilic syndrome.” — Dr. Amal Assa'ad   “I would [consider], for each particular person: What is it that makes their symptoms flare up?” — Dr. Amal Assa'ad   “There were first case reports, and then there were retrospective population studies that found that certain seasons were more associated with either diagnosing EoE or flare-ups of EoE.” — Dr. Amal Assa'ad   “What the patient wants and what the patient needs should be our focus.” — Dr. Amal Assa'ad

The latest guidance for Paxlovid treatment following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; Update on the efficacy of a COVID-19 vaccine in those aged under 5; And the latest on Monkeypox.

Are you trying to weigh the pros and cons of possibly using a biologic like Dupixent for your skin condition? Your immune system has such a complex relationship with one another, so it's important to have complete informed consent when starting one. Look into all the side effects- they could be actually helpful, but they could also lead to cancer! My guest today, Heather Zwickey, earned a Ph.D. in Immunology and Microbiology from the University of Colorado and completed a postdoctoral fellowship and taught at Yale University School of Medicine. Dr. Zwickey is recognized internationally as an expert and educator in the fields of integrative medicine, natural therapies and the immune system and has been leading natural medicine research for 20 years. Heather speaks at conferences world-wide, sharing her enthusiasm for naturopathic medicine and science. She currently serves as the Director of Communication and Innovation at Thaena Inc., a microbiome-based company. Join us as we talk about how biologic drugs for chronic skin conditions work. Did you know about the relationship between your immune system and your skin? Let me know in the comments! In this episode: Biologic drugs - what are they, how are they prescribed, and what do they do? Real side effects of biologics - the bad and even the good Breaking down what cytokines are (in layman's terms) Cytokines and the JAK/STAT pathway Discussion of JAK inhibitors (the newest version of biologic drugs for skin issues) Quotes “Back when we used things like methotrexate for skin disorders, we would see that the entire immune system was blocked and as a result, there would be side effects of things like cancer. When we're only blocking one protein, we have much less severe side effects.” [2:59] “If your skin is not in balance with its microbes, it will affect your gut. We really got to address that. That is the root cause, and usually the way that we're going to address that is with eating more plant-based foods and getting some of the toxins out of our system, and letting those microbes grow the way that they were supposed to grow in normal ecosystems.” [17:47]  Links Find Dr. Zwickey online here Healthy Skin Show ep. 180:  How Hormones Impact Your Immune System + Skin Health w/ Heather Zwickey, PhD Healthy Skin Show ep.157: How Your Immune System Can Trigger Skin Rashes w/ Heather Zwickey, PhD Follow Dr. Zwickey on Instagram

Après le net repli de la veille, le CAC 40 a tenté de repartir de l'avant aujourd'hui, mais il a plié vers la fin de séance clôturant sur un repli de 0,57% vers les 6.462 points et 4,17 milliards d'euros échangés. Il faut dire qu'hier, ce sont les minutes du dernier comité de politique monétaire de la Fed qui sont venues rappeler aux investisseurs la détermination de la banque centrale américaine à lutter contre l'inflation : les membres de la Réserve fédérale estiment notamment que des hausses de 50 points de base du taux des fonds fédéraux pourraient être nécessaire pour calmer la surchauffe des prix. Une réduction de la taille du bilan dès le mois de mai est aussi sur la table avec l'objectif d'atteindre au bout de trois mois un rythme mensuel de réduction de 95 milliards de dollars. Même cause même effets de l'autre côté de l'Atlantique pour les marchés américains qui signent pour l'instant leur 3e séance dans le rouge d'affilée avec les taux sur les bons du Trésor américains à 10 ans s'élevant à 2,64% autour de leurs plus hauts depuis trois ans. Le Dow Jones recule de 0,7% vers les 34.255 points à 17h45 et le Nasdaq à -0,86% vers les 13.770 points. Valeurs en hausse On retrouve une nouvelle fois des valeurs défensives à l'image d'Eurofins Scientific :  cinq séances à la suite pour le groupe qui termine en tête du SBF 120. GTT est aussi bien orienté malgré le repli du Brent qui est repassé sous le seuil des 100 dollars le baril.  L'équipementier auto Faurecia rebondit après deux séances de fort repli tout comme Sodexo qui met enfin un terme à une séquence de six journées consécutives dans le rouge. Sur le CAC 40 en plus d'Eurofins, on retrouve Carrefour, Danone et Sanofi qui gagne 1,6%. La pharma a annoncé que la Commission européenne avait approuvé son médicament Dupixent pour le traitement des enfants âgés de six à onze ans présentant un asthme sévère. Valeurs en baisse Atos reste sous pression, 3e séance de correction et un repli qui est désormais de plus de 41% depuis le début de l'année. 4e plus fort du SBF 120 sur la période. JCDecaux, Solutions30 et Interparfums sont également mal orientés. Alors que sur le CAC 40 c'est encore compliqué pour Alstom, Veolia et Société Générale.

Est-on enfin en train d'avancer dans les pourparlers entre Ukrainiens et Russes ? C'est clairement le scénario auquel les investisseurs ont envie de croire alors que l'Ukraine a proposé d'adopter un statut neutre en échange de garanties pour sa sécurité. De son côté, Moscou évoque une réduction radicale son activité militaire en direction de Kiev et Tcherniguiv, ce qui permettrait de desserrer l'étau autour de la capitale ukrainienne. Il n'en fallait pas plus aux marchés pour se projeter vers la fin du conflit et le CAC 40 clôture la séance sur une nette progression de 3,08% vers les 6792 points et 5,2 milliards d'euros échangés.  Aux Etats-Unis, la hausse est plus mesurée on va dire, mais ça monte tout de même de concert pour le Dow Jones et la Nasdaq à 17h45 : +0,6% pour le premier vers les 35.170 points, +1,2% pour le second vers les 14.533 points. Valeurs en hausse Forcément, les valeurs attaquées récemment rebondissent nettement, c'est le cas pour toutes les valeurs du secteur auto : Faurecia, Valeo, Plastic Omnium, Renault qui sont pied au plancher aujourd'hui avec des hausses à deux chiffres A noter aussi sur le SRD la hausse de 20% d'Actia Group. En marge de ses résultats annuels, le groupe a annoncé qu'il est en train de concrétiser deux opérations de cession d'activités non stratégiques de sa division automotive. Sur le CAC 40, dans le sillage de Renault, on retrouve Worldline, Société Générale et Alstom. Carmat aussi bat plus fort : +40%. La société a annoncé le redémarrage de la production de son coeur artificiel et la confirmation de l'objectif d'une reprise des implantations en octobre. La medtech avait suspendu volontairement ses implantations le 2 décembre dernier en raison de problèmes qualité ayant affecté certaines de ses prothèses. Valeurs en baisse Forcément, on arbitre chez les investisseurs avec les valeurs qui se sont appréciées sur ces dernières semaines et donc on vend.. Thales, lanterne rouge du SBF 120 Ca baisse aussi pour Sanofi. La pharma a annoncé qu'elle visait désormais, un chiffre d'affaire "à plus de 13 milliards d'euros en rythme de croisière" pour le Dupixent, son traitement de l'asthme et de la dermatite atopique. Une prévision un peu inférieure aux attentes du marché Les pétrolières et parapétrolières marquent également logiquement le pas comme Vallourec ou TotalEnergies, GTT, tout comme les valeurs liées aux métaux comme Eramet ou Arcelormittal.

Did you know that about 10% of people using Dupixent develop awful face and neck dermatitis? This issue (more officially called Dupilumab Facial Redness (DFR)) wasn't flagged during the randomized FDA trials, but has some dermatologists concerned because DFR can be incredibly severe, just as it was for one of my clients. Since Dupixent is a biologic drug used by some with Eczema and Topical Steroid Withdrawal to ease symptoms, this new problem isn't ideal. Rather than just assume that the person has a sensitivity to Dupixent, new research is showing that this may be a different problem — Malasezzia hypersensitivity. If you recall, Malasezzia is a fungal organism that normally lives in your skin's microbiome. It really shouldn't be causing an issue like this, but something about the way that Dupixent interacts with your immune system along with a compromised skin barrier could play a role. Here are the current papers discussing this topic so you have something to bring to your prescribing dermatologist so you can get the help you need if you are experiencing this! In this episode: Facial + neck redness that occurs in about 10% of Dupixent users What current research on what may be driving this weird “side effect” Treatment options listed in currently published articles The blood test marker that could be helpful in getting a clear diagnosis What to do if YOU have face + neck redness from Dupixent Quotes: Approximately 10% of Dupixent users develop red, inflamed, dry, scaly and itchy face + neck rashes requiring antifungal medication treatment. Dupixent Facial Redness was never described or mentioned in the Dupixent clinical trials for the FDA (which is surprising considering that it impacts approximately 10% of patients).

Should you use dupixent if you're going through eczema or topical steroid withdrawal (TSW) flares? Dupixent is a biologic medication - and my guest, Dr. Ana-Maria Temple - shares her thoughts about using dupixent for eczema and TSW flares. Dr. Ana-Maria Temple is an integrative pediatrician, award-winning speaker at Harvard Club of Boston, and a frequent guest on TV news and talk shows.  Book a free breakthrough call here. For more eczema tips, follow Abby on: Facebook - facebook.com/eczemaconquerors Instagram - instagram.com/eczemaconquerors YouTube -  youtube.com/user/eczemaconquerors Website - eczemaconquerors.com Want more eczema resources?  Shop my Conqueror line of products to help your skin find relief here: https://store.primephysiquenutrition.com/collections/all *Use the code PODCAST10 for 10% off your order here.  

I'm coming to you fresh off a TM Class, the Johnson & Johnson vaccine and a Free Palestine protest, all before 1pm! Hey congrats on still being here, there's a lot of crap going on and the immediate gratification of not having to deal with it gives one hell of a strip tease. Hell is on earth, but heaven is in your mind. On today's episode of The Voices In Our Heads: A weird week with birds Man Thinks Woman Cares About Stats Don't take Dupixent if you're allergic to Dupixent A grandma sews a family back together in a stranger's dream (MaGiCaL email) A look at Chapter 2 of Letting Go: The Pathway To Surrender by David R. Hawkins all about the mechanism of surrender. --> Patreon --> Email--> Website--> The Gram

I'm coming to you fresh off a TM Class, the Johnson & Johnson vaccine and a Free Palestine protest, all before 1pm! Hey congrats on still being here, there's a lot of crap going on and the immediate gratification of not having to deal with it gives one hell of a strip tease. Hell is on earth, but heaven is in your mind. On today's episode of The Voices In Our Heads: A weird week with birds Man Thinks Woman Cares About Stats Don't take Dupixent if you're allergic to Dupixent A grandma sews a family back together in a stranger's dream (MaGiCaL email) A look at Chapter 2 of Letting Go: The Pathway To Surrender by David R. Hawkins all about the mechanism of surrender. --> Patreon --> Email --> Website --> The Gram Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode, Ayesha discusses the latest trends in pharma tv ad spending, including the top spenders last week. The pandemic has led to a rise in both TV watching and health awareness, which pharma companies took advantage of by increasing spending on TV commercials by about 17 percent overall. Last week, three of the top ten TV ads by expenditure were from pharma, which included GLP-1 diabetes drugs Rybelsus and Trulicty and the anti-inflammatory Dupixent for treating eczema. The group also talked about a new AI algorithm developed by researchers at the Mayo Clinic that can help increase the identification and diagnosis of cases of low ejection fraction. Low ejection fraction is often asymptomatic in early stages and hence goes underdiagnosed in many instances. The new AI algorithm is integrated into routine electrocardiograms (ECG), which are fast and readily accessible but cannot diagnose the condition on their own. The team discussed the promise of integrating AI approaches into existing medical tools and technologies to facilitate enhanced diagnoses and treatments.Read the full articles here:Pharma TV Ad Spending Trends: Companies in the Top Ten this WeekHow a New AI Algorithm Could Help in the Early Detection of Heart DiseaseFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

E no episódio temos um eu aceito, Tiffany & Co cria anel de casamento para homens, falamos também sobre o #robotaxi na China.Você já conhece o primeiro desodorante adaptado para pessoas com deficiência visual e de membros superiores? Então venha ver o Degree Inclusive da Unilever. Quanto gasta a Farma em publicidade e quais foram os TOP 5 produtos que mais gastaram em 2020: Humira, Dupixent, Xeljanz, Skyrizi e OzempicTodas as Segundas!

We speak with Dr. Patricia Loftus from UCSF Otolaryngology - Head & Neck Surgery discussing her clinical and surgical approach to treating Nasal Polyps. --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs: https://earnc.me/UPOA4g --- SHOW NOTES In this episode, Dr. Patricia Loftus joins Dr. Gopi Shah and Dr. Ashley Agan to outline the diagnosis and management of patients with nasal polyps. They identify common presenting symptoms and physical exam findings as well as discuss the roles of imaging, culture, and biopsy. Medical management including the risks and benefits of antibiotics and oral steroids are reviewed. Endoscopic surgical approaches and their utility in different clinical presentations are described. Pre-, peri- and post-operative considerations are also discussed. The discussion then evolves to focus on conditions that clinicians should be aware of including allergic fungal sinusitis (AFS), cystic fibrosis (CF), primary ciliary dyskinesia (PCD), and central compartment atopic disease (CCAD). Finally, they highlight recent developments in management including the role of biologic therapies such as Dupixent. --- RESOURCES Dr. Loftus' Email Address: Patricia.Loftus@UCSF.edu Women in Rhinology Twitter Handle: @Women_Rhinology Women in Rhinology Instagram: @women_in_rhinology Biologics for Nasal Polyps: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013513.pub2/full

Women In Government Podcast It Takes 2: Type 2 Inflammation People of all ages, genders, and backgrounds are connected by similar challenges because of one lesser known chronic condition known as Type 2 Inflammation. Recent scientific developments have shown that this overactive immune system response, underlies different atopic, allergic and inflammatory diseases. What exactly does that mean and how does it affect our families and communities? On this episode of the Women In Government Podcast, our panel discusses how the type 2 inflammation connection can help patients work with their doctors to gain control of their chronic disease. As for policymakers and industry leaders, these chronic conditions impact communities of color and those in underserved communities. Now's the time to get to work and support measures to address type 2 inflammation. ••••• ••••• ••••• MODERATOR: Melissa Hurtado, California State Senator GUEST #1: Carole Huntsman, Head, Sanofi Genzyme North America and US Country Lead GUEST #2: Dr. Mandeep Kaur, Vice President, Head, North America Medical for Dupixent at Sanofi Genzyme GUEST #3: Dr. Tyra Bryant-Stephens MD, Director and Founder, The Community Asthma Prevention Program, Clinical Professor of Pediatrics, The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania ••••• ••••• ••••• For more information, including a Spanish-language translation transcript of this podcast, please visit www.womeningovernment.org Audio courtesy of OSUCHLUCK Productions, www.osuchluck.com

Today's pod covers important news regarding hydroxychloroquine; The efficacy of dietary supplements as a means to manage or prevent COVID-19; The first non-hormonal contraceptive gel approved by the FDA; And an expanded approval for dupilumab.

If you've considered starting Dupixent or some other type of biologic medication for your rashes, here's something to consider. Problems (that aren't significant enough to be major issues yet) can be lurking under the surface and go unnoticed. If a biologic medication works, symptoms should go away. That's a great thing for your confidence, peace of mind, and daily level of comfort. But it can cause you to miss clues (aka. symptoms) that need attention sooner rather than later. In today's episode, I'm sharing why symptoms are like your car's “check engine” light AND how this all played out for a client in real life. My client wanted to share her experience to inspire you to “take a look under the hood” to make sure there's nothing else going on that does need some TLC. Because once you start a biologic (and it works), you lose out on using your symptoms as a guide towards better health. In this episode: Isn't it a good thing to block inflammation that's wrecking your skin? Symptoms are like your car's “check engine” light Jessica's experience living with eczema (and why she was recommended a biologic) Digging into Jessica's case revealed deeper issues Why you should get your system checked thoroughly before turning to a biologic Words of wisdom from my client Jessica Quotes: If Jessica had taken a biologic (assuming it cleared up her skin), she would have never known about any of the other issues hiding under the surface. Symptoms aren't meant to mentally and emotionally devastate you, nor make you feel like you're at war with your body.

I share the science behind steroid creams and Dupixent to treat eczema. I prefer a more natural way to heal, and that through food. Remember guys: FOOD is the ultimate medicine! My website: www.healthyskincoach.co Best skin probiotic: https://www.skinesa.com/?aff=5 Best eczema cream: https://us.gladskin.com/?utm_medium=affiliate&utm_source=blog&utm_campaign=tastytakos --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/healthyskincoach/message

Today's guest is Ashley Ann Lora, an eczema patient advocate who used the medication, Dupixent, for several years and has successfully withdrawn from it for over 20 weeks so far (which she says, is rare to see). She shares the emotional healing, mindset, and morning rituals that have helped her on her journey. She was also on the Dr. Phil show to share her eczema journey. Please note that this episode is in no way promoting Dupixent as a medication, but this episode is here to promote the emotional healing practices that Ashley has adopted since her Dupixent withdrawal.  ----------------------- For more eczema tips, follow Abby on Facebook, Instagram, or YouTube for more eczema tips and updates.   Want more eczema resources?  Click here for more eczema resources or visit my list of recommended products for eczema! You can also find products to help your skin below: Shop all eczema products Conqueror Dry Skin Soothing Balm Conqueror Eczema Academy group coaching program Eczema eBooks  Calming Bath Treatment  Eczema gloves *Use the code PODCAST10 for 10% off your order.